Norfloxacin Dosage for SBP Prophylaxis in Cirrhotic Patients

Indications for SBP Prophylaxis

The European Association for the Study of the Liver recommends that patients who have recovered from a previous episode of SBP should receive continuous prophylaxis with norfloxacin 400 mg once daily 1, 2, 3
Secondary prophylaxis with norfloxacin reduces the probability of SBP recurrence from approximately 70% to 20% in patients with a history of SBP 2, 4
Without prophylaxis, the 1-year mortality after an episode of SBP is 50-70%, making prevention crucial in high-risk patients 4

The American Association for the Study of Liver Diseases suggests that ciprofloxacin 500 mg once daily orally can be used as an alternative to norfloxacin for SBP prophylaxis in cirrhotic patients 2, 5, 6
Co-trimoxazole (800 mg sulfamethoxazole and 160 mg trimethoprim) once daily orally is another alternative option for SBP prophylaxis in patients who cannot tolerate norfloxacin or ciprofloxacin 5, 6

Norfloxacin prophylaxis significantly reduces mortality in the first three months (94% vs 62% survival) in patients with a history of SBP 4
Fluoroquinolones carry risks of side effects including tendon inflammation and damage, particularly in patients with renal impairment 6
Long-term quinolone prophylaxis may increase the risk of gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus 2

The European Association for the Study of the Liver recommends that all patients with a history of SBP should be considered for liver transplantation evaluation, as they have poor long-term survival 2, 4
Regular monitoring of renal function is recommended in patients on prophylactic antibiotics, such as norfloxacin or ciprofloxacin 5
Consider restricting proton pump inhibitor use in patients on SBP prophylaxis, as PPIs may increase SBP risk 6, 4

Bacterial resistance is an increasing concern with long-term fluoroquinolone use, and local bacterial resistance patterns should be considered when selecting prophylactic antibiotics 6, 7
Always consider local bacterial resistance patterns when selecting prophylactic antibiotics, and avoid weekly ciprofloxacin regimens that may lead to higher rates of quinolone-resistant organisms 5, 7, 4

The European Association for the Study of the Liver recommends primary prophylaxis for patients with low ascitic fluid protein (<15 g/L) and advanced liver disease or impaired renal function, with Norfloxacin 400 mg daily as the first-line agent 8, 9, 10
Patients with Child-Pugh score ≥9, serum bilirubin ≥3 mg/dL, impaired renal function, or hyponatremia are at high risk and should receive primary prophylaxis 8

The American Association for the Study of Liver Diseases recommends secondary prophylaxis for all patients who have recovered from a previous episode of SBP, with Norfloxacin 400 mg daily as the first-line agent 8, 9, 10
Without prophylaxis, the recurrence rate at 1 year is approximately 70%, and one-year survival after SBP is only 30-50% 10

Norfloxacin reduces the one-year probability of developing SBP from 61% to 7% and improves three-month survival probability from 62% to 94% 8
Norfloxacin also reduces the risk of hepatorenal syndrome and SBP recurrence from 68% to 20% 8, 10

The European Association for the Study of the Liver recommends restricting proton pump inhibitor (PPI) use in cirrhotic patients, as PPIs may increase SBP risk 8
Patients on prophylactic antibiotics should be monitored for signs of tendon pain or inflammation, and discontinue at first sign 10
Regular monitoring of renal function is recommended in patients on prophylactic antibiotics, and diagnostic paracentesis should be performed if clinical deterioration occurs 9, 10